TargaZyme Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • 2ndary - Private

TargaZyme General Information

Description

Developer of enzyme-based cell-therapy medicines designed to improve therapeutic-cell delivery, engraftment, and efficacy for cancer and other serious diseases. The company's medicines use proprietary fucosyltransferase enzymes and small molecules to enhance therapeutic-cell trafficking, tissue penetration, and engraftment, enabling medical practitioners to improve clinical efficacy and the development of treatments for cancer, blood disorders, autoimmune diseases, and other conditions where inefficient cell delivery limits therapeutic efficacy.

Contact Information

Formerly Known As
America Stem Cell
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 2100 Palomar Airport Road
  • Suite 214-19
  • Carlsbad, CA 92011
  • United States
+1 (760)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Corporate Office
  • 2100 Palomar Airport Road
  • Suite 214-19
  • Carlsbad, CA 92011
  • United States
+1 (760)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TargaZyme Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private Completed Clinical Trials - Phase 3
7. Later Stage VC 01-Jan-2017 Completed Clinical Trials - Phase 3
6. Grant 27-Jul-2015 Completed Clinical Trials - Phase 2
5. Grant 31-Jul-2014 Completed Clinical Trials - Phase 2
4. Grant 07-Jan-2013 Completed Clinical Trials - Phase 2
3. Grant 02-Apr-2012 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 15-Jul-2009 $1.25M $1.25M Completed Startup
1. Grant 01-Feb-2007 $5M Completed Startup
To view TargaZyme’s complete valuation and funding history, request access »

TargaZyme Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of enzyme-based cell-therapy medicines designed to improve therapeutic-cell delivery, engraftment, and efficac
Biotechnology
Carlsbad, CA
10 As of 2026

San Carlos, CA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TargaZyme Competitors (15)

One of TargaZyme’s 15 competitors is Iovance Biotherapeutics, a Corporation company based in San Carlos, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Iovance Biotherapeutics Corporation San Carlos, CA
Gamida Cell Formerly VC-backed Boston, MA
Poseida Therapeutics Formerly VC-backed San Diego, CA
Nkarta Therapeutics Formerly VC-backed South San Francisco, CA
Gesynta Pharma Venture Capital-Backed Stockholm, Sweden
You’re viewing 5 of 15 competitors. Get the full list »

TargaZyme Patents

TargaZyme Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4719441-A1 Compositions, systems, and methods for combinatorial therapies containing fucosylated cells and chemokines and/or scaffolds for autoimmune conditions and regenerative medicine Pending 24-May-2023
EP-4676498-A2 Compositions and systems for combinatorial therapies containing fucosylated stem cells and hematopoietic enhancers and/or immunotherapeutics Pending 08-Mar-2023
WO-2024187122-A3 Compositions and systems for combinatorial therapies containing fucosylated stem cells and hematopoietic enhancers and/or immunotherapeutics Inactive 08-Mar-2023
US-20260345686-A1 Compositions and systems for combinatorial therapies containing fucosylated stem cells and hematopoietic enhancers and/or immunotherapeutics and methods of production and use thereof Pending 08-Mar-2023
WO-2024187122-A2 Compositions and systems for combinatorial therapies containing fucosylated stem cells and hematopoietic enhancers and/or immunotherapeutics and methods of production and use thereof Inactive 08-Mar-2023 A61K35/28
To view TargaZyme’s complete patent history, request access »

TargaZyme Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TargaZyme FAQs

  • When was TargaZyme founded?

    TargaZyme was founded in 2005.

  • Where is TargaZyme headquartered?

    TargaZyme is headquartered in Carlsbad, CA.

  • What is the size of TargaZyme?

    TargaZyme has 10 total employees.

  • What industry is TargaZyme in?

    TargaZyme’s primary industry is Biotechnology.

  • Is TargaZyme a private or public company?

    TargaZyme is a Private company.

  • What is TargaZyme’s current revenue?

    The current revenue for TargaZyme is .

  • How much funding has TargaZyme raised over time?

    TargaZyme has raised $32.2M.

  • Who are TargaZyme’s competitors?

    Iovance Biotherapeutics, Gamida Cell, Poseida Therapeutics, Nkarta Therapeutics, and Gesynta Pharma are some of the 15 competitors of TargaZyme.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process